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Urotensin II (UII) is a potent vasoactive hormone in mammals.
However, despite its well-known effects on epithelial sodium
transport in fish, little is known about its actions on the
mammalian kidney. The aim of this study was to determine
the effects of UII on renal function in the rat. Using standard
clearance methods, the effects of rUII and the rat UII receptor
(UT) antagonist, urantide, were studied. UII was measured in
plasma and urine by radioimmunoassay. UII and UT were
localized in the kidney by immunohistochemistry and mRNA
expression quantified. Rat urinary [UII] was 1650-fold higher
than that in plasma. Immunoreactive-UII was localized to the
proximal tubules, outer and inner medullary collecting ducts
(IMCD); UT receptor was identified in glomerular arterioles,
thin ascending limbs, and IMCD. UII and UT mRNA expression
was greater in the medulla; expression was higher still in
spontaneously hypertensive rats (SHRs) associated with
raised plasma (UII). Injection of rUII induced reductions in
glomerular filtration rate (GFR), urine flow, and sodium
excretion. Urantide infusion resulted in increases in these
variables. Endogenous UII appears to contribute to the
regulation of GFR and renal sodium and water handling in
the rat. While hemodynamic changes predominate, we
cannot rule out the possibility of a direct tubular action of UII.
Increased expression of UII and UT in the SHR suggests that
UII plays a role in the pathophysiology of cardiovascular
disease.
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The peptide hormone urotensin II (UII), originally char-
acterized in fish,1 attracted considerable attention following
its cloning in man 2 and identification as the endogenous
ligand for the rat orphan G-protein-coupled receptor GPR14
and its human homolog,3,4 now designated the UT receptor.5
Initially, a number of conflicting vasoactive actions were
attributed to UII in mammals, including humans,6–8 non-
human primates, 3,9 and rats.9,10 These observations are likely
attributable to methodological differences rather than the
heterologous nature of the peptide often employed: the
mammalian UT receptor cannot distinguish between rat,
mouse, monkey, human, and goby UII.11,12 It is now
apparent that UII evokes a variety of vasoactive responses,
which differ between species and the different vascular beds
of a single species. This has led to the suggestion that UII
contributes to cardiovascular regulation and may be
implicated in cardiovascular disease.13–16
One aspect of mammalian UII physiology that has
received little attention is its potential role in body fluid
regulation. Several studies have implicated UII in the
conservation of water,17,18 sodium, and chloride 19,20 in fish
species. In the absorptive tissues of teleost fish, such as
urinary bladder and intestine, UII stimulates active sodium
and chloride uptake from luminal fluid. In secretory tissues,
such as opercular skin, UII inhibits active sodium and
chloride transport.21 These observations demonstrate that
UII can directly influence epithelial ion transport. This raises
the possibility that UII may contribute to the regulation of
renal function in mammals. This hypothesis is supported by
reports of prepro-UII mRNA expression in human22–24 and
primate kidneys.25 Indeed, Nothaker et al.25 suggested that
the kidney was the principal site of UII synthesis in humans,
while Matsushita et al.23 proposed that the human UII (hUII)
measured in urine was derived mainly from a renal source.
Immunoreactive-UII expression has also been described in
human renal blood vessels and epithelial cells.26,27 High
affinity binding of human [125I]UII has been reported at low
levels in the human renal cortex,10 consistent with the
reported expression of UT receptor mRNA in human 23,28
and primate kidney.24 However, despite the cloning of rat
prepro-UII,29 expression of UII has not been described in this
species. There is limited information available concerning UT
receptor expression in the rat from an early report, which
identified sensory epithelial neuropeptide-like receptor
(SENR, renamed the UT receptor) in rat neural and sensory
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tissues.30 However, this approach failed to identify UT
receptor expression in the rat kidney.
UII is not the only ligand that binds to the UT receptor.
An octapeptide, urotensin-related peptide (URP), has been
identified in humans, mice, and rats.31 URP shares a high
degree of homology with the cyclic region of the UII
molecule, which is the site that confers biological activity.
Competitive binding assays revealed that URP binds and
activates the UT receptor with high potency and affinity.
However, the precursor proteins of URP and UII are quite
different, sharing only 18.8% amino-acid homology in
humans. A comparison of prepro-UII and prepro-URP gene
expression in human and rat tissues revealed a similar pattern
of distribution. Prepro-URP was expressed predominantly in
the spinal cord and testes of both species; interestingly,
prepro-URP was detected in human kidney but not that of
the rat.31
Intrarenal infusion of hUII has been reported to induce a
nitric oxide-dependent increase in renal blood flow that was
accompanied by a diuresis and natriuresis in the rat.32
However, the concentrations of UII induced in these
experiments were supraphysiological. Accordingly, the aim
of this study was to determine the renal response of the rat to
exogenous rat UII (rUII) at physiologically relevant concen-
trations. We also sought to identify the influence of
endogenous UII on renal function through inhibition of
the rat UT receptor by the peptide antagonist, urantide.33 A
rat UII radioimmunoassay was developed to determine
plasma and urinary concentrations of UII. Our antibody
was raised against the cyclic region of UII, which is shared
with URP, so we also tested its crossreactivity with URP. As
both the plasma 34 and urinary 23 concentrations of UII are
elevated in human essential hypertension, we also measured
plasma UII in the spontaneously hypertensive rat (SHR).
Finally, we localized UII and UT receptor expression within
the kidney, and quantified mRNA expression of UII, URP,
and UT receptor, to identify the potential glomerular and
tubular site(s) of UII action.
RESULTS
Plasma and urine UII concentrations
The anti-UII antibody crossreacted with URP, pro-UII, and
the UII fragment hUII [5–11] under radioimmunoassay
conditions: it did not crossreact with the linearized hUII
[5–10], fragment over the working range of the assay (data
not shown). Therefore, in the following description of data,
the term immunoreactive-UII refers to mature rUII, pro-UII,
bioactive mature rat UII fragments and URP.
Immunoreactive-UII was detected in the plasma and urine
of Sprague–Dawley (SD) rats: the concentration in urine was
3.270.5 109 M, some 1650-fold higher than in plasma
from the same animals (1.970.5 1012 M, n¼ 5, Po0.001).
The concentration of UII in SHR plasma was signifi-
cantly higher than that in Wistar Kyoto (WKY) rat plasma
(WKY, n¼ 9, 11.871.4 1012 M vs SHR, n¼ 13,
20.471.9 1012 M, P¼ 0.003).
UII, UT receptor, and URP location and mRNA expression
Immunoreactive-UII was detected in the proximal tubules
(Figure 1a–c), with weaker staining present in the distal
tubules; no immunostaining was observed in either the
glomerulus or the arterioles. Immunoreactive-UII was also
detected in both the outer (Figure 1d) and inner medullary
collecting ducts (IMCD) (Figure 1e), extending deep into the
papilla. Immunostaining for UII was absent in control
sections (preadsorbed with antigenic peptide, Figure 1f).
UII mRNA expression was significantly higher in the
medulla by comparison with cortex (cortex, n¼ 6,
0.2870.22 103 vs medulla, n¼ 5, 2.2571.32 103
copies/rpL32, P¼ 0.039). URP mRNA was also detected;
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Figure 1 | Immunoreactive-UII immunostaining in SD rat kidney. (a–c) In the cortex, immunoreactive-UII was localized to the proximal
convoluted tubule (PCT), with weaker staining in the distal tubule (DT) (Glomerulus – G). (d) Immunoreactive-UII was observed in the collecting
ducts (CD), but not the thin limbs (tL) in the medulla. (e) Immunoreactive-UII was also seen in the IMCD of the papilla. (f) Control cortical
section. Original magnification:  200.
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medullary expression levels tended to be higher than that
in cortex, but this did not achieve statistical significance
(cortex, n¼ 6, 0.4670.44 103 vs medulla, n¼ 5,
2.2971.65 103 copies/rpL32, P¼ 0.068). There was no
difference between the relative expression levels of UII and
URP mRNA in either cortex or medulla (F1,21¼ 0.83,
P¼ 0.37).
Immunostaining for the UT receptor was observed only
occasionally in the cortex, being restricted to glomerular
arterioles and distal tubules adjacent to the glomerulus
(Figure 2a–d). Immunostaining was absent in control
sections (no primary antibody, Figure 2e). In the medulla,
immunostaining was present in the inner medullary collect-
ing duct (Figure 2f) and thin limbs of Henle´ (Figure 2g). In
order to differentiate between the descending and ascending
thin limbs, serial sections were stained for either AQP1
(Figure 2h) or the UT receptor (Figure 2i). Descending thin
limbs expressing AQP1 did not stain for the UT receptor and
vice versa (compare Figures 2h and i), suggesting that UT
receptor expression is limited to the ascending thin limbs.
This is consistent with the expression of UT mRNA, which
was more abundant in the medulla than the cortex of SD rats
(cortex, n¼ 6, 0.2370.19 103 vs medulla, n¼ 5,
2.2471.32 103 copies/rpL32, P¼ 0.039).
Similarly, UII mRNA expression was significantly higher
in the medulla of SHR by comparison with cortex (Po0.01,
Figure 3). WKY rats tended towards a comparable difference;
however, this did not achieve statistical significance. URP
mRNA expression was also significantly higher in the medulla
of SHR by comparison with the cortex (Po0.05, Figure 3).
However, in contrast to the pattern seen for UII mRNA, URP
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Figure 2 | UT receptor immunostaining in SD rat kidney. (a–d) The only cortical structures that expressed the UT receptor were the
glomerular arterioles and distal tubules adjacent to the glomerulus. (e) Control cortical section. (f) UT was also expressed in the IMCD of the
papilla. (g) UT was observed in the thin limbs (tL) but not the thick ascending limbs (TAL) of the medulla. Descending and ascending thin limbs
were differentiated by means of AQP1 expression, which only occurs in descending thin limbs.45 Compare the serial section in (h), which was
immunostained for AQP1 with that in (i), which was immunostained for the UT receptor. The location of UT receptor-positive cells identified in
(i) is indicated on section (h) by arrows. Original magnification: (a, f–i) 200, (b–e) 400.
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Figure 3 | Relative expression of UII, URP and UT mRNA,
normalized to the housekeeping gene rpL32, in the renal cortex
(&) and medulla (’) of WKY (n¼ 6) and SHR (n¼ 5) rats. Data are
shown as the mean7s.e.m. Statistical analysis was by one-way
analysis of variance and Duncan’s test. *Po0.05, **Po0.01 cortex vs
medulla within the same strain; þ þPo0.01 WKY medulla vs SHR
medulla; Po0.05 WKY cortex vs SHR cortex.
1362 Kidney International (2006) 69, 1360–1368
o r i g i n a l a r t i c l e W Song et al.: Renal actions of urotensin II
mRNA in the SHR kidney tended to be reduced by
comparison with the WKY kidney: this reached statistical
significance for the cortex (Po0.05, Figure 3). UT mRNA
expression was significantly higher in the medulla by
comparison with the cortex of both WKY (Po0.05) and
SHR (Po0.001) rats (Figure 3). Furthermore, UT mRNA
expression was greater in the medulla of SHR compared with
WKY kidneys (Po0.01, Figure 3).
Effect of UII administration on renal function
Bolus injection of rUII produced a dose-related reduction in
blood pressure. At 0.6 pmol rUII/100 g body weight there were
small, but significant, reductions in systolic (DSBP, n¼ 10,
4.671.0 mmHg, P¼ 0.003) and diastolic (DDBP, n¼ 10,
9.473.2 mmHg, P¼ 0.025) blood pressure 15 min after
injection. These changes were associated with a significant
tachycardia (D heart rate, n¼ 10, 27.072.4 b.p.m., Po0.001).
The pattern of response was similar, but of greater magnitude,
at 6 pmol rUII/100 g body weight. Systolic (DSBP, n¼ 10,
7.070.7 mmHg, Po0.001) and diastolic (DDBP, n¼ 10,
15.371.7 mmHg, Po0.001) blood pressure fell, whereas
heart rate increased (D heart rate, n¼ 10, 24.871.5 b.p.m.,
Po0.001). Blood pressure remained constant in vehicle-
injected control animals (DSBP, n¼ 7, 1.670.6 mmHg,
P¼ 0.052; DDBP, n¼ 7, 0.470.7 mmHg, P¼ 0.57); how-
ever, there was a small, but significant, reduction in heart rate
(D heart rate, n¼ 7, 3.170.5 b.p.m., P¼ 0.001).
UII had a dose-related effect on both renal hemodynamics
and electrolyte handling. For clarity, data are presented only
for the effects of rUII administration at 6.0 pmol/100 g body
weight. The effects induced by rUII at 0.6 pmol/100 g body
weight were essentially the same, but of smaller magnitude.
Rat UII injection induced a transient reduction in effective
renal blood flow (ERBF, control hour mean 8.070.5 vs
15 min after rUII injection 4.470.9 ml min1 100 g body
weight1 P¼ 0.038); this was not sustained, returning to
basal levels after 15 min (F1,12¼ 0.97, P¼ 0.35). There was a
more pronounced effect on glomerular filtration rate (GFR),
which was significantly reduced for 30 min post-rUII
injection (P¼ 0.001, Figure 4a) before returning to control
levels for the remaining 30 min (F1,15¼ 2.1, P¼ 0.17).
This pattern was reflected in urine flow and electrolyte
excretion rates. However, the recovery back towards rates
exhibited by the time-matched control group after 30 min
was less pronounced. Hence, rUII injection induced sig-
nificant reductions in urine flow (F1,15¼ 5.5, P¼ 0.03, Figure
4b), sodium (F1,15¼ 4.5, P¼ 0.05, Figure 4c), potassium
(F1,15¼ 13.6, P¼ 0.002, Figure 4d), calcium (F1,15¼ 5.9,
P¼ 0.03, data not shown), and magnesium (F1,15¼ 9.6,
P¼ 0.007, data not shown) excretion rates for 1 h. Reduc-
tions in electrolyte excretion were accompanied by a trend
towards lower fractional excretion rates, but this was only
significant for potassium (F1,15¼ 11.9, P¼ 0.004). In the
15 min immediately after rUII injection, when the fall in
electrolyte excretion was near maximal, only fractional
excretion of potassium was significantly lower than that of
the vehicle infused group (P¼ 0.006, Table 1). In contrast,
the clearance rates of sodium (P¼ 0.02), potassium
(Po0.001), and magnesium (P¼ 0.01) were significantly
reduced by comparison with the vehicle-treated animals over
the same time period (Table 1).
Effect of UII antagonist administration on renal function
Urantide had no effect on heart rate (F1,13¼ 1.07, P¼ 0.32),
systolic (F1,13¼ 0.04, P¼ 0.86), or diastolic (F1,13¼ 0.002,
P¼ 0.97) blood pressure over 2 h.
ERBF did not change during urantide infusion
(F1,13¼ 0.03, P¼ 0.86, data not shown); however, there was
a modest but significant increase in GFR (F1,13¼ 5.76,
P¼ 0.03, Figure 5a), which reached a peak of
1.270.2 ml min1 100 g body weight1 after 30 min, com-
pared with 0.870.1 ml min1 100 g body weight1 in the
vehicle-treated group (P¼ 0.04). This increase in GFR was
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Figure 4 | Effect of UII on GFR, urine flow rate (UV), urinary
excretion of sodium (UNaV), and potassium (UKV) in anesthetized
SD rats. After a 3 h equilibration period, control urine samples were
collected for 1 h before an i.v. bolus injection of UII (6.0 pmol/100 g
body weight, dashed line, n¼ 10) or vehicle (150 mM NaCl, solid line,
n¼ 7) was given (indicated by arrow). Urine samples were collected
for a further hour. Data are shown as the mean7s.e.m. for each
15 min sample period. See text for details of statistical analysis.
Table 1 | Renal clearance (CX, where X is the electrolyte Na
+,
K+, Ca2+, or Mg2+, ll min1 100 g bwt1) and fractional
excretion (FEX, where X is the electrolyte Na
+, K+, Ca2+, or
Mg2+, %) rates of electrolytes in anesthetized SD rats 15 min
after an i.v. bolus injection of either rat UII (6.0 pmol/100 g
body weight) or vehicle (150 mM NaCl)
Vehicle (n=7) Urotensin II (n=10)
CNa 12.472.7 5.971.0*
FENa 1.770.3 1.970.5
CK 360.6732.6 125.2725.2***
FEK 49.574.1 29.774.2**
CCa 14.276.6 5.572.0
FECa 1.770.6 1.370.4
CMg 120.1712.6 58.9715.3**
FEMg 17.072.3 16.774.3
SD, Sprague–Dawley; UII, urotensin II; GFR, glomerular filtration rate.
This time point corresponds with the period of maximal reduction in GFR (Figure
4a). Statistical comparisons were by two-tailed unpaired t-test. *Po0.05, **Po0.01,
***Po0.001 vehicle vs UII.
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not sustained for the whole 2 h of urantide; filtration rate
returned to control levels after 1 h. Urine flow rate was
significantly higher in the urantide-treated animals
(F1,13¼ 25.21, Po0.001, Figure 5b) throughout the 2 h
infusion, though the flow rate began to decline after 90 min.
The diuresis was accompanied by a significant increase in
sodium excretion rate (F1,13¼ 20.2, P¼ 0.001, Figure 5c),
which reached a peak of 6.971.0 mmol min1 100 g body
weight1 at 30 min, compared with 4.170.4 mmol min1
100 g body weight1 in vehicle-treated rats (P¼ 0.001). This
was reflected in increased in sodium clearance (P¼ 0.043) by
urantide-treated rats at 30 min (Table 2). Although fractional
sodium excretion was 44% higher in these animals at this
time, this difference did not reach statistical significance
(P¼ 0.193). In contrast to this natriuretic response, 30 min
into urantide infusion, the excretion rates of potassium
(F1,13¼ 0.004, P¼ 0.95, Figure 5d), calcium (vehicle
0.0370.01 vs urantide 0.0370.01 mmol min1 100 g body
weight1 F1,13¼ 1.45, P¼ 0.25,) and magnesium (vehicle
0.0970.01 vs urantide 0.1070.01 mmol min1 100 g body
weight1 F1,13¼ 0.01, P¼ 0.92) were unaltered. Apart from
the fractional potassium excretion, which was lower in the
urantide-treated group (P¼ 0.02), the clearance and frac-
tional excretion rates of these ions did not differ from the
vehicle-treated group (Table 2).
DISCUSSION
This study has shown that rUII administered at low
concentrations influences water and electrolyte handling by
the rat kidney. Furthermore, infusion of the UII antagonist
urantide revealed an unknown influence of endogenous UII
on GFR and sodium and water excretion. Together with the
UII and UT receptor immunohistochemistry, these observa-
tions suggest that UII contributes to the regulation of sodium
and water handling by the rat kidney.
The reductions in ERBF, GFR, urine flow and sodium
excretion rates induced by rUII contrast with the observa-
tions of Zhang et al.,32 who reported increases in the same
parameters in response to hUII. There are two possible
explanations for these differences: duration of administration
and the dose of UII employed. We gave a single intravenous
(i.v.) bolus dose of rUII into the femoral vein, whereas Zhang
et al.32 employed continuous infusion directly into the renal
artery. This may have affected the nature of the vascular
response, as Bennett et al. have reported that infusion of UII
(for 2 h) evoked opposite vascular effects to bolus dosing in
the conscious rat; bolus injections resulted in vasodilata-
tion,35 while constant infusion produced vasoconstriction
(Br J Pharmacol 2002; 135: 200P). We also employed a lower
dose of rUII, administered into the systemic circulation, than
Zhang et al.32 who introduced 75–600 pM hUII directly into
the renal artery. This low dose of rUII was chosen in order to
study the potential renal actions of rUII in the absence of
marked fluctuations in systemic pressure.
The new radioimmunoassay revealed a circulating
immunoreactive-UII concentration in the naı¨ve SD rat in
the low pM range (0.6–3.6 pM), suggesting that circulating
concentrations rUII induced in the current experiments
represent a physiologically relevant stimulus. This is sup-
ported by the effects of urantide, a full UT receptor
antagonist in the rat,36 on renal function. In this experiment,
GFR, urine flow rate, and sodium excretion rate increased,
which is consistent with the observed effects of bolus rUII
administration, suggesting that endogenous UII exerts a tonic
influence on these parameters in vivo.
The reported effects of UII on renal vessels are contra-
dictory. A nitric oxide-dependent vasodilatation was ob-
served when hUII was given intrarenally to anesthetized
rats.32 This is consistent with an earlier report of an increase
in blood space (i.e. vasodilatation) in the renal cortex
following UII administration.37 In contrast, Gardiner et al. 35
have reported a reduction in renal blood flow in conscious
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Figure 5 | Effect of the UT receptor antagonist urantide on GFR,
urine flow rate (UV), the urinary excretion of sodium (UNaV), and
potassium (UKV) in anesthetized SD rats. After a 3-h equilibration
period, control urine samples were collected for 1 h before the
infusate was switched to urantide at 0.02 mg kg1 min1 (dashed line,
n¼ 8) or vehicle (150 mM NaCl, solid line, n¼ 8) for a further 2 h. Data
are shown as the mean7s.e.m. for each 15 min sample period. See
text for details of statistical analysis.
Table 2 | Renal clearance (CX, where X is the electrolyte Na
+,
K+, Ca2+, or Mg2+, ll min1 100 g bwt1) and fractional
excretion (FEX, where X is the electrolyte Na
+, K+, Ca2+, or
Mg2+, %) rates of electrolytes in anesthetized SD rats after
infusion of either the UT receptor antagonist urantide
(0.02 mg kg1 min1) or vehicle (150 mM NaCl) for 30 min
Vehicle (n=8) Urantide (n=8)
CNa 31.673.1 52.378.0*
FENa 3.970.4 5.671.2
CK 344.9731.3 390.9721.7
FEK 59.975.0 39.975.1*
CCa 18.774.4 22.575.9
FECa 2.470.6 2.570.8
CMg 178.2715.0 252.9741.7
FEMg 24.472.9 26.775.9
SD, Sprague–Dawley.
This time point corresponds with the period of maximal diuresis and natriuresis
(Figure 5b and c). Statistical comparisons were by two-tailed unpaired t-test.
*Po0.05 vehicle vs urantide.
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rats following bolus injection of UII, but only at the highest
dose employed in their study (300 pmol/kg). In the current
study, we observed dose-related reductions in ERBF and GFR
upon bolus rUII administration, and an increase in GFR
(though not ERBF) during urantide infusion. It is unlikely
that this fall in GFR following UII injection was due entirely
to a fall in systemic blood pressure, other than in the
immediate postinjection period. Systemic blood pressure had
recovered back to control levels within 20 min, yet GFR was
reduced for 30 min after UII injection. This suggests that UII
had a more direct influence on glomerular hemodynamics,
through constriction of the afferent or dilatation of the
efferent arterioles. Unfortunately, it was not possible to
localize arteriolar UT expression unequivocally, so we cannot
be certain of the mechanisms underlying the observed
UII-induced fall in GFR.
The rUII-induced changes in renal hemodynamics were
associated with reductions in urine flow and sodium
excretion rates: the reverse of effects observed during
urantide infusion. This could be explained by changes in
GFR alone; indeed, sodium fractional excretion was not
significantly lower following UII injection. However, there is
some evidence to suggest that UII may also have a tubular
site of action. Early studies demonstrated that UII stimulates
uptake of sodium and chloride from the lumen of absorptive
tissues in fish.17,38,39 In the current study, sodium excretion
was still reduced 1 h after UII injection, despite GFR having
returned to control levels. UT receptor mRNA expression was
detected in both the cortex and medulla, with greatest
expression found in the latter. Immunohistochemistry
showed that cortical expression was limited to glomerular
arterioles and juxtaglomerular distal segments, whereas
medullary UT expression was abundant in the thin ascending
limbs and IMCD. The significance of UT receptor expression
in the IMCD is not clear, but its presence in a nephron
segment where hormonal fine tuning of urine composition
occurs raises the possibility that UII may influence electrolyte
transport. Potassium excretion certainly appears to be
influenced by UII: potassium fractional excretion was lower
following UII injection. Urantide infusion had a similar
effect, against a background of diuresis, which suggests that
the fall in the potassium fractional excretion was acting to
maintain potassium balance under these conditions.
It is worth noting that the presence of immunoreactive-
UII was detected in the proximal tubules and both the outer
and IMCD, with weaker staining in the distal tubules. As our
antibody, in common with others, recognizes both pro-UII
and URP, as well as mature UII and bioactive fragments, we
cannot be sure that this immunostaining represents UII
alone. The pattern of immunoreactive-UII expression in the
human kidney was somewhat different. Greatest expression
was observed in the distal tubules and collecting ducts,
with weaker expression in proximal tubules and loops of
Henle´ and only occasional expression in glomeruli.26 UII is
found in human urine;23 fractional hUII excretion exceeded
GFR, suggesting that human kidney is a source of UII.23
These observations are consistent with the high immunor-
eactive-UII concentration in rat urine herein. Even allowing
for maximal urine concentration, it is unlikely that the UII
detected in the urine was derived solely from filtered UII.
This suggests that the kidney is a source of UII in the rat and
that it may act as a paracrine factor as well as a circulating
hormone.
UII has been implicated in the pathophysiology of
cardiovascular and renal disease. Plasma34 and urinary23
concentrations of UII are elevated in human essential
hypertension; plasma UII is also elevated in patients with
renal dysfunction 22 and in type II diabetics with renal
nephropathy.40 This study provides further evidence in
support of the potential role of UII in cardiorenal disease.
The plasma immunoreactive-UII concentration and renal
medullary UII and UT mRNA expression were increased in
SHRs. Interestingly, URP mRNA expression was diminished
in kidneys from SHR, implying that there is an increase in the
intrarenal UII/URP ratio in this model of hypertension.
Further work is now required to determine the role of UII
and URP in the onset of hypertension.
In summary, this study has demonstrated that immuno-
reactive-UII is present in both the circulation and urine of
the rat. The rat kidney expresses UT receptors in the
glomerular arterioles, juxtaglomerular distal tubules, thin
ascending limbs, and IMCD; it is also a source of UII, which
may act as a paracrine hormone on renal epithelial cells.
When administered as an i.v. bolus injection, rUII induced a
reduction in GFR and the excretion of sodium and water:
these effects were the reverse of those observed during
infusion of the UT receptor antagonist urantide. Together
these data suggest that UII contributes to the regulation of
both GFR and sodium and water excretion in the rat kidney.
This raises the possibility that UII antagonists may have
therapeutic value in the treatment of conditions of volume
overload, such as heart failure,41 by acting as a diuretic.
MATERIALS AND METHODS
Experiments were performed in accordance with the UK Animals
(Scientific Procedures) Act 1986 and received local ethical approval.
Animals
Male SD, WKY, and SHR rats (190–250 g, Charles River UK Ltd,
Kent, UK) were housed under standard conditions (22–241C with a
12 h light:12 dark cycle) with free access to water and standard chow
(Rat & Mouse Standard Diet, Bantin & Kingman Ltd, North
Humberside, UK).
Materials
Unless stated otherwise, all reagents were purchased from Sigma-
Aldrich Company Ltd, Dorset, UK.
UII radioimmunoassay
SD rats (n¼ 5) were anesthetized with Intraval (thiopentone
sodium, 110 mg/kg i.p., May & Baker Ltd, Essex, UK) and a urine
sample was withdrawn by bladder puncture and stored at 801C.
The rats were decapitated and a trunk blood sample collected in
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ice-cold tubes containing 0.125 M EDTA. After centrifugation at
2000 g for 5 min at 41C, separated plasma was stored at 801C.
Trunk blood was collected from SHR (n¼ 13) and WKY rats
(n¼ 9), killed by stunning followed by decapitation. Before assay,
proteins were extracted from plasma samples by reverse-phase
chromatography using C18 SepPak cartridges (Waters Ltd, Hert-
fordshire, UK) with acetonitrile solvent. Urine samples were assayed
without extraction.
The concentration of UII was measured by a novel radio-
immunoassay based on that described by Winter et al.42 A rabbit
polyclonal antibody was raised against flounder UII (P Ingleton,
University of Sheffield, UK), which possesses the conserved sequence
(CFWKYC) found in all known UII.43 It does not crossreact with
urotensin I, angiotensin II, endothelin I, or somatostatin-14.6,42
Crossreactivity was tested against pro-UII (GlaxoSmithKline, King
of Prussia, PA, USA), URP, the UII fragment human (h) UII [5–11],
and a linearized fragment hUII [5–10] (California Peptide Research
Inc., CA, USA). 125I-labelled rUII (Peptide Institute, Inc., Osaka,
Japan) was prepared by the Iodogen method.44 Plasma and urine
samples were incubated with the UII antibody (diluted 1:12800)42
and 125I-labelled rUII at 41C for 24 h. Antibody bound 125I-labelled
rUII was separated by addition of bovine g-globulin and
polyethylene glycol, centrifugation (2000 g for 20 min at 41C), and
aspiration before counting on a Cobra II gamma counter (Packard,
Berkshire, UK).
A typical standard curve is shown in Figure 6. A parallel curve is
also plotted for serial dilutions of rat urine, demonstrating validity
for use in urine analysis; the assay was validated similarly for use in
plasma analysis (data not shown). Recovery of rUII from plasma was
67711% (n¼ 10); inter- and intra-assay coefficients of variation
were 12.3% (n¼ 10) and 9.2% (n¼ 10); detection limit was
1.6 1015 M per tube.
UII and UT receptor immunohistochemistry
SD rat kidneys (n¼ 5) were perfusion-fixed with 4% paraformalde-
hyde in phosphate-buffered saline, dehydrated in ethanol
(50–100%), and embedded in paraffin wax. Sections (5 mM) were
incubated overnight at 41C with either the polyclonal rabbit anti-
flounder UII antibody (1:1000 dilution) or a polyclonal rabbit anti-
rat UT receptor antibody (1:100 dilution, Santa Cruz Biotechnology,
CA, USA) diluted in 0.1% BSA, 0.3% Triton X-100 in phosphate-
buffered saline. Preliminary studies showed that the UT receptor was
expressed in the thin loop of Henle´. In order to differentiate between
descending and ascending thin limbs, alternating serial sections were
incubated with either a polyclonal rabbit anti-rat aquaporin 1
antibody (AQP1, 1:200 dilution, D Marples, University of Leeds,
UK), as a marker of the descending thin limb,45 or the polyclonal
rabbit anti-rat UT receptor antibody. Labelling was identified by
application of a goat anti-rabbit HRP-conjugated secondary anti-
body (1:750 for anti-UII, 1:500 for anti-UT, 1:100 for anti-AQP1,
DakoCytomation Ltd, Cambridgeshire, UK) before incubation with
diaminobenzidine. Negative controls were carried out by preincu-
bating the primary antibody with an excess of immunizing peptide,
and by omission of either the primary or secondary antibodies.
UII, UT receptor, and URP quantitative TaqMan reverse
transcriptase-polymerase chain reaction
Total RNA was extracted from SD (n¼ 6), WKY (n¼ 6), and SHR
(n¼ 5) renal cortical and medullary tissue using a Qiagen RNeasy
Mini kit (Qiagen, Inc., CA, USA). Primers and TaqMan probes
(Table 3) for rat UII, UT, URP, and ribosome protein L32 (rpL32)
were designed using Primer Express software. All TaqMan probes
were labelled with FAM and TAMRA as the reporter and quencher
dyes, respectively. Reverse transcriptase-polymerase chain reaction
was performed using the ABI Prism 7700 system (Applied
Biosystems), according to the manufacturer’s instructions. Copy
numbers were calculated based upon standard curves generated
with 10-fold dilutions of genomic DNA over 6 log units starting
from 100 000 copies to one copy. Data were normalized to the mean
copy numbers from rpL32 and performed in separate reverse
transcriptase-polymerase chain reaction reactions.
Effect of UII administration on renal function
Intraval-anesthetized SD rats were prepared for renal function study
as described previously.46 Briefly, the femoral vein was cannulated
for infusion of vehicle and drugs, and the femoral artery to record
blood pressure (PowerLab 800/s, ADInstruments, East Sussex, UK)
and the withdrawal of blood samples. A catheter was implanted in
the bladder for urine collection.
After surgery, rats received a priming dose of 4 mCi 3H inulin
(Amersham Pharmacia Biotech, Essex, UK) and 12 mg para-
aminohippuric acid in 0.3 ml 150 mM NaCl and then placed on a
continuous i.v. infusion of 150 mM NaCl containing 3H inulin
(0.3 mCi/h) and para-aminohippuric acid (3 mg/h) at 50 ml/min.
Table 3 | Primer sequences (50 to 30) for UII, URP, UT receptor and the house keeping gene rpL32
Gene name TaqMan probe Forward Reverse
UII TGAGCCGTCTTTTGGCGAGAACC CTGGGCAAGATTCTAACACTGTA CGTGTTGCTTACGTTGTTTCC
URP TGCTGAGCCGTCCAATGCTTTAGACAA TGAGAGAATGGTTTATGGAGGCA CAAGCTCGTTTAATAGGGTGGGA
UT TGGTCATGTGCCGGTTTCTGCG GGGCATGGTGGGAAATGTAT AGACGTACATGGAGGCCGAG
rpL32 AGCAGCACAGCTGGCCATCAGAGTC AACCGAAAAGCCATCGTAGAAA CCTGGCGTTGGGATTGG
URP, urotensin related peptide; UII, urotensin II; URP, urotensin related peptide.
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Figure 6 | Typical radioimmunoassay curve for rat UII, with
antibody bound 125I rat UII expressed as a percentage of
maximum label binding (B0) (’) plotted against the concentra-
tion of rat UII. An antibody binding curve for serial dilutions of rat
urine is also shown (J), demonstrating parallelism of the two curves.
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After 3 h, urine samples were collected every 15 min over a 1 h
control period; a blood sample (0.5 ml) was taken mid-way through
the hour. Rats were divided into three groups, which received an i.v.
injection of either vehicle (0.2 ml 150 mM NaCl, n¼ 7) or rUII at
0.6 pmol/100 g body weight (n¼ 10), or 6.0 pmol/100 g body weight
(n¼ 10). Urine samples were collected every 15 min for a further
hour; a blood sample (0.5 ml) was taken once per hour.
Effect of UII antagonist administration on renal function
An effective dose of the rat UT receptor antagonist urantide [Pen5,
DTrp7, Orn8]hU-II(4–11)33 (California Peptide Research Inc., CA,
USA) was determined in a pilot experiment. The lowest dose of
urantide that was able to block the fall in mean arterial pressure
induced by a bolus i.v injection of rUII (0.6–6.0 pmol/100 g body
weight, data not shown) was identified.
A group of SD rats was infused with 150 mM NaCl and clearance
markers. After 3 h equilibration, control urine samples were
collected every 15 min for an hour; a blood sample (0.5 ml) was
taken mid-way through the hour. Rats then either continued to
receive vehicle (150 mM NaCl, n¼ 8) or received an i.v. bolus
injection of urantide (0.2 mg/kg, n¼ 8) followed by a continuous
infusion of urantide at 0.02 mg kg1 min1 for 2 h. Urine samples
were collected every 15 min; a blood sample (0.5 ml) was taken once
per hour.
Urine and plasma analysis
Sodium and potassium were measured by flame photometry (model
480, Ciba Corning Diagnostics Ltd, Essex, UK); calcium and
magnesium by atomic absorption spectrophotometry (model 3100,
Perkin Elmer, Bucks, UK). Osmolality was measured by freezing
point depression (LH Roebling, Berlin, Germany). 3H inulin activity
was determined using a 1900CA Tri-Carb Liquid Scintillation
Analyser (Canberra Industries, CT, USA) b-counter. Para-amino-
hippuric acid concentration was measured using a standard
colorimetric assay.
Statistical analysis
Data are presented as the mean7s.e.m. Data were tested for
normality of distribution and were normalized by log10 transforma-
tion where necessary. Statistical analysis was by two-tailed Student’s
t-test for paired or independent samples, repeated measures analysis
of variance, or one-way analysis of variance and Duncan’s test,
with significance at Po0.05 (SPSS for Windows, SPSS UK Ltd,
Surrey, UK).
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